Acute and chronic effects of electroconvulsive treatment on oxidative parameters in schizophrenia patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1689-1694

  Kartalci, Sukru ^a   Karabulut, Aysun Bay ^a   Ozcan, Abdul Cemal ^a   Porgali, Esra ^a   Unal, Suheyla ^a  

^a INONU UNIVERSITY   (Turkey)

Author keywords

Electroconvulsive therapy; Oxidative stress; Schizophrenia

Indexed keywords

CATALASE; GLUTATHIONE; MALONALDEHYDE; NITRIC OXIDE;

ACUTE DISEASE; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; BRIEF PSYCHIATRIC RATING SCALE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RATING SCALE; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCALE FOR THE ASSESSMENT OF POSITIVE SYMPTOMS; SCHIZOPHRENIA; SMOKING;

ADULT; ANTIOXIDANTS; CATALASE; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79961126642     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.05.007     Document Type: Article

References (56)

1. Aebi H. Catalase. Methods of enzymatic analysis 1974, 673-677. Academic Press, New York. H.U. Bergmeyer (Ed.).
2. Akyol O., Herken H., Uz E., Fadilliof̌lu E., Unal S., Söǧüt S., et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:995-1005.
3. Al-Chalabi B.M., Thanoon I.A., Ahmed F.A. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology 2009, 59:8-11.
4. American Psychiatric Association The practice of ECT: recommendations for treatment, training and privileging. Task force report on ECT 1990, American Psychiatric Press, Washington, DC.
5. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) 1983, University of Iowa, Iowa City.
6. Andreasen N.C. Scale for the Assessment of Positive Symptoms (SAPS) 1983, University of Iowa, Iowa City.
7. Barichello T., Bonatto F., Agostinho F.R., Reinke A., Moreira J.C., Dal-Pizzol F., et al. Structure-related oxidative damage in rat brain after acute and chronic electroshock. Neurochem Res 2004, 29:1749-1753.
8. Ben Othmen L., Mechri A., Fendri C., Bost M., Chazot G., Gaha L., et al. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:155-159.
9. Cooper S.J., Scott A.I., Whalley L.J. A neuroendocrine view of ECT. Br J Psychiatry 1990, 157:740-743.
10. Corapcioglu A., Aydemir O., Yildiz M., Koroglu E. DSM-IV Eksen I Bozukluklari (SCID-I) i̇cin Yapilandirilmis Klinik Goruşme. Klinik Versiyon 1999, Hekimler Yayin Birligi, Ankara.
11. Cortas N.K., Wakid N.W. Determination of inorganic nitrate in serum and urine by a kinetic cadmium reduction method. Clin Chem 1990, 36:1440-1443.
12. Dakhale G., Khanzode S., Khanzode S., Saoji A., Khobragade L., Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49:205-209.
13. Dal-Pizzol F., Klamt F., Vianna M.M., Schröder N., Quevedo J., Benfato M.S., et al. Lipid peroxidation in hippocampus early and late after status epilepticus induced by pilocarpine or kainic acid in Wistar rats. Neurosci Lett 2000, 291:179-182.
14. Dietrich-Muszalska A., Olas B., Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005, 16:386-391.
15. Do K.Q., Trabesinger A.H., Kirsten-Krüger M., Lauer C.J., Dydak U., Hell D., et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000, 12:3721-3728.
16. Fairbanks V., Klee G.G. Biochemical aspects of hematology. Textbook of clinical chemistry 1986, 1532-1534. W.B. Saunders, Philadelphia. N.W. Tietz (Ed.).
17. Feier G., Jornada L.K., Barichello T., Vitali A.M., Bonatto F., Moreira J.C., et al. Long lasting effects of electroconvulsive seizures on brain oxidative parameters. Neurochem Res 2006, 31:665-670.
18. Fendri C., Mechri A., Khiari G., Othman A., Kerkeni A., Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encéphale 2006, 32:244-252.
19. Fink M. Convulsive therapy: a review of the first 55years. J Affect Disord 2001, 63:1-15.
20. Halliwell B., Gutteridge J.M.C. Free radicals in biology and medi̇cine 2000, 617-624. Oxford University Press, Oxford Science Publications, London. third ed.
21. Herken H., Uz E., Ozyurt H., Söǧüt S., Virit O., Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001, 6:66-73.
22. Herken H., Uz E., Ozyurt H., Akyol O. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr Res 2001, 52:289-290.
23. Jornada L.K., Feier G., Barichello T., Vitali A.M., Reinke A., Gavioli E.C., et al. Effects of maintenance electroshock on the oxidative damage parameters in the rat brain. Neurochem Res 2007, 32:389-394.
24. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002, 58:1-10.
25. Kreisman N.R., Rosenthal M., Sick T.J., LaManna J.C. Oxidative metabolic responses during recurrent seizures are independent of convulsant, anesthetic, or species. Neurology 1983, 33:861-867.
26. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E.,i̇cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002, 20:171-175.
27. Lepping P., Delieu J., Mellor R., Williams J.H.H., Hudson P.R., Hunter Lavin C. Antipsychotic medication and oxidative cell stress: a systematic review. J Clin Psychiatry 2011, 72:273-285.
28. Li H.C., Chen Q.Z., Ma Y., Zhou J.F. Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J Zhejiang Univ Sci B 2006, 7:981-986.
29. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996, 19:1-7.
30. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:463-493.
31. Matsuzawa D., Obata T., Shirayama Y., Nonaka H., Kanazawa Y., Yoshitome E., et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One 2008, 3:e1944.
32. Mihara M., Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978, 86:271-278.
33. Newman M.E., Gur E., Shapira B., Lerer B. Neurochemical mechanisms of action of ECS: evidence from in vivo studies. J ECT 1998, 14:153-171.
34. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11:851-876.
35. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol Rep 1962, 10:799-812.
36. Padurariu M., Ciobica A., Dobrin I., Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010, 479:317-320.
37. Patel M.N. Oxidative stress, mitochondrial dysfunction, and epilepsy. Free Radic Res 2002, 36:1139-1146.
38. Patel M. Mitochondrial dysfunction and oxidative stress: cause and consequence of epileptic seizures. Free Radic Biol Med 2004, 37:1951-1962.
39. Petronijević N.D., Mićić D.V., Duricić B., Marinković D., Paunović V.R. Substrate kinetics of erythrocyte membrane Na, K-ATPase and lipid peroxides in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:431-440.
40. Raffa M., Mechri A., Othman L.B., Fendri C., Gaha L., Kekreni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1178-1183.
41. Reddy R., Keshavan M., Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003, 62:205-212.
42. Sultana R., Piroddi M., Galli F., Butterfield D.A. Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 2008, 33:2540-2546.
43. Taneli F., Pirildar S., Akdeniz F., Uyanik B.S., Ari Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res 2004, 35:401-405.
44. Taylor S. Electroconvulsive therapy: a review of history, patient selection, technique, and medication management. South Med J 2007, 100:494-498.
45. Terpstra M., Henry P.G., Gruetter R. Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra. Magn Reson Med 2003, 50:19-23.
46. Vaiva G., Thomas P., Leroux J.M., Cottei̇cin O., Dutoit D., Erb F., et al. Erythrocyte superoxide dismutase (eSOD) determination in positive moments of psychosis. Therapie 1994, 49:343-348.
47. Virit O., Dalkilic A., Bulut M., Bulbul F., Altindag A., Armutcu F., et al. Decreased superoxide dismutase activity after ECT and correlation between higher oxidant levels and poor response to ECT in depression. Arch Neuropsychiatry 2010, 47:247-251.
48. Wood S.J., Yucel M., Pantelis C., Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann Acad Med Singapore 2009, 38:396-406.
49. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 1998, 32:385-391.
50. Yao J.K., Reddy R.D., van Kammen D.P. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol Psychiatry 1999, 45:1512-1515.
51. Yao J.K., Reddy R., van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000, 97:137-151.
52. Yao J.K., Leonard S., Reddy R.D. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull 2004, 30:923-934.
53. Yao J.K., Leonard S., Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 2006, 22:83-93.
54. Zhang M., Zhao Z., He L., Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci 2010, 53:112-124.
55. Zoroglu S.S., Herken H., Yürekli M., Uz E., Tutkun H., Savaş H.A., et al. The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiatr Res 2002, 36:309-315.
56. Zupan G., Pilipović K., Hrelja A., Peternel S. Oxidative stress parameters in different rat brain structures after electroconvulsive shock-induced seizures. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:771-777.